Andorra vs Small island developing states (SIDS): Proportion of the target population who received
Andorra
97.0%
in 2024
Small island developing states (SIDS)
63.0%
in 2024
Andorra rank
18th
Small island developing states (SIDS) rank
16th
Proportion of the target population who received over time
- Andorra
- Small island developing states (SIDS)
How they compare
Andorra currently reports 97.0% against 63.0% in Small island developing states (SIDS), a difference of 34.0%.
That makes Andorra's figure about 1.5 times Small island developing states (SIDS)'s.
Across all 18 years both countries report, Andorra has been ahead every year.
Andorra ranks 18th and Small island developing states (SIDS) ranks 16th of 165 countries.
Andorra has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Andorra | Small island developing states (SIDS) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 82.7% | 28.0% | 54.7% | Andorra |
| 2010s | 90.2% | 31.6% | 58.6% | Andorra |
| 2020s | 95.8% | 56.8% | 39.0% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received, Andorra or Small island developing states (SIDS)?
- Andorra, at 97.0% against 63.0% in Small island developing states (SIDS) as of 2024.
- What is the difference in proportion of the target population who received between Andorra and Small island developing states (SIDS)?
- 34.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Small island developing states (SIDS)?
- 18 years are reported by both, from 2007 to 2024.
- How do Andorra and Small island developing states (SIDS) rank globally for proportion of the target population who received?
- Andorra ranks 18th and Small island developing states (SIDS) ranks 16th of 165 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.